Literature DB >> 10779670

Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks.

M Ashina1, L Bendtsen, R Jensen, S Schifter, J Olesen.   

Abstract

Although calcitonin gene-related peptide (CGRP) has been shown to be elevated in jugular venous blood of adult migraineurs during acute migraine attacks, it remains unknown whether CGRP is increased outside of attacks in jugular or cubital venous blood. The aim of the present study was to compare interictal plasma levels of CGRP in adult migraine patients and in healthy controls. Twenty patients with a diagnosis of migraine with or without aura and 20 healthy controls were included. In blood from the cubital vein, CGRP levels were significantly higher in patients (75+/-8 pmol/l (mean+/-SEM)) than in controls (49+/-3 pmol/l) (P=0.005). The subgroup of patients suffering exclusively from migraine without aura (n=14) also had significantly higher levels of CGRP (82+/-10 pmol/l) than controls (n=20; 49+/-3 pmol/l) (P=0.001). The findings could not be explained by confounding factors such as age, sex or use of contraceptive pills. We therefore conclude that CGRP is increased in cubital venous blood of migraineurs outside of attack. It is hypothesized that this finding may reflect a long-lasting or permanent abnormal neurogenic vascular control in patients with migraine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10779670     DOI: 10.1016/s0304-3959(00)00232-3

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  49 in total

1.  Pharmacological evidence for CGRP uptake into perivascular capsaicin sensitive nerve terminals.

Authors:  A Sams-Nielsen; C Orskov; I Jansen-Olesen
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

Review 2.  Chemical mediators of migraine: preclinical and clinical observations.

Authors:  Saurabh Gupta; Stephanie J Nahas; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

Review 3.  Inhibition of calcitonin gene-related peptide function: a promising strategy for treating migraine.

Authors:  Paul L Durham
Journal:  Headache       Date:  2008-09       Impact factor: 5.887

Review 4.  Diclofenac potassium for oral solution (CAMBIA®) in the acute management of a migraine attack: clinical evidence and practical experience.

Authors:  Shivang Joshi; Alan M Rapoport
Journal:  Ther Adv Neurol Disord       Date:  2017-02-08       Impact factor: 6.570

5.  Effects of the CGRP receptor antagonist BIBN4096BS on capsaicin-induced carotid haemodynamic changes in anaesthetised pigs.

Authors:  Kapil Kapoor; Udayasankar Arulmani; Jan P C Heiligers; Ingrid M Garrelds; Edwin W Willems; Henri Doods; Carlos M Villalón; Pramod R Saxena
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

Review 6.  Migraine: where and how does the pain originate?

Authors:  Karl Messlinger
Journal:  Exp Brain Res       Date:  2009-03-14       Impact factor: 1.972

7.  Genetic enhancement of calcitonin gene-related Peptide-induced central sensitization to mechanical stimuli in mice.

Authors:  Blanca Marquez de Prado; Donna L Hammond; Andrew F Russo
Journal:  J Pain       Date:  2009-07-22       Impact factor: 5.820

8.  Plasma calcitonin gene-related peptide concentration is comparable to control group among migraineurs and tension type headache subjects during inter-ictal period.

Authors:  Ravi Gupta; Tanzeel Ahmed; Basudeb Banerjee; Manjeet Bhatia
Journal:  J Headache Pain       Date:  2009-03-11       Impact factor: 7.277

Review 9.  Does exercise make migraines worse and tension type headaches better?

Authors:  Nada Ahmad Hindiyeh; John Claude Krusz; Robert Paul Cowan
Journal:  Curr Pain Headache Rep       Date:  2013-12

10.  Migraine may be a risk factor for the development of complex regional pain syndrome.

Authors:  B L Peterlin; A L Rosso; S Nair; W B Young; R J Schwartzman
Journal:  Cephalalgia       Date:  2010-02       Impact factor: 6.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.